

Programme

Wednesday July 5, 2017

08:00 Registration & Welcome Coffee

09:30 RICT 2017 Opening

Michel BALTAS (CNRS, UNIVERSITY OF TOULOUSE, Toulouse, France)
Armand LATTES (UNIVERSITE PAUL SABATIER, Toulouse, France)
Alexis VALENTIN (UNIVERSITÉ PAUL SABATIER, Toulouse, France)
Luc VAN HIJFTE (SCT & NOVITHERA, Nijmegen, The Netherlands)

Session 1: Paul Ehrlich Award Lecture
Sponsored by Janssen Research & Development

Session Chairs

Jean-François BONFANTI (JANSSEN R&D, Val de Reuil, France)
Luc VAN HIJFTE (SCT & NOVITHERA, Nijmegen, The Netherlands)

10:00 PL01 - Sugars & Proteins: Glycomimetics to Target Infectious Disease

Benjamin DAVIS
(OXFORD UNIVERSITY, Oxford, United Kingdom)

11:00 Coffee break & Exhibition

Session 2: Peptides & Sugars in Drug Discovery

Session Chair

Olivier LAVERGNE
(, Palaiseau, France)

11:30 PL02 - Peptide Drugs to Target GPCR- State of the Art and Innovative Application

Annette BECK-SICKINGER
(LEIPZIG UNIVERSITY, Leipzig, Germany)

12:15 Lunch break & Exhibition

13:00 Poster Session 1 (odd numbers) & Exhibition

Session 3: Recent Advances in Immuno-oncology
Sponsored by Evotec

Session Chair

Gilbert LASSALLE
(EVOTEC, Toulouse, France)

14:30 PL03 - Small Molecule Approaches in Immune Modulation in Cancer.

Ronan O'HAGAN
(MERCK, SHARP & DOHME, Boston, United States)

15:15 PL04 - Immunotherapy of Cancers: The Lessons of Oncodermatology; Melanoma as a Model

Programme

Nicolas MEYER
(ONCOPOLE TOULOUSE, Toulouse, France)

16:00 Coffee break & Exhibition

16:30 PL05 - Novel Small Molecule MerTK Inhibitors and their Biological Uses

Xiaodong WANG
(UNIVERSITY OF NORTH CAROLINA, Chapel Hill, United States)

17:15 PL06 - Discovery of PF-06840003, a Novel IDO Inhibitor for Cancer Immunotherapy

Stefano CROSIGNANI
(ITEOS THERAPEUTICS SA, Gosselies, Belgium)

18:00 Welcome & Networking Reception

19:30 End of Day 1

Programme

Thursday July 6, 2017

Session 4: Inspired by Nature

Session Chair

Michel BALTAS
(CNRS, UNIVERSITY OF TOULOUSE, Toulouse, France)

08:30 PL07 - De Novo Drug Design — Inspiration from Nature

Gisbert SCHNEIDER
(ETH ZÜRICH, Zürich, Switzerland)

Session Session 4: Inspired by Nature

Session Chair

Michel BALTAS
(CNRS, UNIVERSITY OF TOULOUSE, Toulouse, France)

09:15 KL01 - New Modalities inspired by nature: from Genetic Encoding of Cyclic Peptides to Hybrid Macrocycles

Eric VALEUR
(ASTRAZENECA, IMED BIOTECH UNIT, Cambridge, United States)

09:45 KL03 - Post-functionalization of RNAs for Specific Conjugations with Peptides and Proteins

Mélanie ETHEVE-QUELQUEJEU
(UNIVERSITY PARIS DESCARTES, Paris, France)

Session Session 5: Advances in Kinase Inhibitors Discovery

Session Chair

Jean-Yves ORTHOLAND
(EDELIRIS, Lyon, France)

09:15 KL02 - Mnk1/2 Kinase Inhibitors for the Treatment of Leukemia

Kassoum NACRO
(EXPERIMENTAL THERAPEUTICS CENTER, Singapore, Singapore)

09:45 KL04 - Discovery of CDK8/CDK19 Kinase Modulators and Evaluation of their Therapeutic Potential

Aurelie MALLINGER
(INSTITUTE OF CANCER RESEARCH, London, United Kingdom)

10:15 Coffee break & Exhibition

Session Session 6: Accessing Novel Chemical Space

Session Chair

Janos SAPI
(SCT & UNIVERSITY OF REIMS-CHAMPAGNE-ARDENNE, Reims, France)

10:45 PL08 - Expanding Screening Decks by Innovative MCR Scaffolds

Alexander DÖMLING
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

11:30 PL10 - Chemoselective and Biocompatible Reactions, New Tools for Heterocyclic Chemistry and Chemical Biology

Frédéric TARAN
(CEA/SACLAY, Gif-sur-Yvette, France)

Session Session 7: Structure Based Design

Session Chair

Jean-Paul RENAUD
(RIBOSTRUCT, Ostwald, France)

10:45 PL09 - First-in-class Extracellular Modulators of Receptor Tyrosine Kinases: from Theory to Practice

Programme

Didier ROGNAN
(CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)

11:30 PL11 - Structure-based Drug Design (SBDD) in Medicinal Chemistry-enabled Drug Discovery

Hong SHEN
(ROCHE INNOVATION CENTER, Shanghai, China)

12:15 Lunch break & Exhibition

13:00 Poster Session 2 (even numbers) & Exhibition

13:45 Career Session

Session Session 8: New Tools for Therapeutic Innovation

Session Chair

YVES GENISSON
(UNIVERSITE PAUL SABATIER - LSPCMIB, Toulouse, France)

14:30 KL05 - Copper and Zinc as Therapeutic Players in Alzheimer's Disease: With a little Help from Coordination Chemistry.

Christelle HUREAU
(LCC CNRS, Toulouse, France)

15:00 KL07 - Nanometric Micelles for *in vivo* Imaging and Drug Delivery

Eric DORIS
(CEA, Gif-sur-Yvette, France)

Session Session 9: Advances in Proteases Inhibitor Discovery

Session Chair

Patrick JIMONET
(SANOFI, Vitry sur Seine, France)

14:30 KL06 - Discovery of Novel TACE Inhibitors for Topical Treatment of Psoriasis

Gilles OUVRY
(GALDERMA R&D, Sophia Antipolis, France)

15:00 KL08 - Mining from NP-Like Fragments in 3D: Discovery of a Potent Caspase-1 Inhibitor

Vincent RODESCHINI
(EDELIRIS, LYON, France)

Session Session 10: Rare Diseases

Session Chair

YVES GENISSON
(UNIVERSITE PAUL SABATIER - LSPCMIB, Toulouse, France)

15:30 PL12 - Partnering Early to Better Serve Patients Suffering from Rare and Devastating Diseases

Jean-Philippe ANNEREAU
(ALEXION, Paris, France)

Session Session 11: Neglected Diseases

Session Chair

Patrick JIMONET
(SANOFI, Vitry sur Seine, France)

15:30 PL13 - Allosteric Inhibitors of Dengue and Zika Virus NS3/NS2B Proteases

Tanja SCHIRMEISTER
(UNIVERSITY OF MAINZ, Mainz, Germany)

16:15 Coffee break & Exhibition

Programme

Session Session 12: Synthetic Biology

Session Chair

Sebastien PAPOT
(UNIVERSITY OF POITIERS, Poitiers, France)

16:45 PL14 - Xeno Nucleic Acids (XNA) *in vivo* : A New Medicinal Chemistry Approach?

Piet HERDEWIJN
(KU LEUVEN, Leuven, Belgium)

17:30 PL16 - Bioactive Ribosomal and Non-Ribosomal Peptides from Nature - Structures, Biosynthesis and Engineering Options

Roderich D. SÜSSMUTH
(TECHNICAL UNIVERSITY BERLIN, Berlin, Germany)

Session Session 13: Tackling PPIs

Session Chair

Andras KOTSCHY
(SERVIER RESEARCH INSTITUTE OF MEDICINAL CHEMISTRY, Budapest, Hungary)

16:45 PL15 - Monitoring the Antagonist-Protein and Protein-Protein Interactions with NMR and X-ray: Inhibitors of the p53-Mdm2 and Immune Checkpoint PD-1/PD-L1 Interactions

Tad HOLAK
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Krakow, Poland)

17:30 PL17 - Engineering Alfabodies to Generate Potent Druggable Inhibitors of Intracellular Protein-Protein Interactions

Ignace LASTERS
(COMPLIX, Zwijnaarde, Belgium)

18:15 End of Day 2

19:00 Cocktail at the City Hall

20:30 Gala Dinner

Programme

Friday July 7, 2017

Session 14: Advances in Kinase Inhibitors Discovery & Development Sponsored by Galapagos

Session Chair

Romain GOSMINI
(NOVALIX, Illkirch-Graffenstaden, France)

08:30 PL18 - Development of Dual IGF1R/INSR Inhibitors - A Case Study

Heather TYE
(EVOTEC LTD, Abingdon, United Kingdom)

09:15 PL19 - Identifying High Quality, Potent and Selective Inhibitors of ATM Kinase for Oncology Therapies: Discovery of AZD0156

Bernard BARLAAM
(ASTRAZENECA, Cambridge, United Kingdom)

10:00 Coffee break & Exhibition

10:30 PL20 - Raising the Gold Standard: Design & Development of Highly Selective JAK3 Probes (Janus Kinase 3)

Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)

11:15 PL21 - Leniolisib (CDZ173) - Discovery of a New Generation of Potent and Selective PI3K? Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases

Nicolas SOLDERMANN
(NOVARTIS, Basel, Switzerland)

Session 15: Pierre Fabre Award Lecture Sponsored by Institut de Recherche Pierre Fabre

Session Chair

Michel PEREZ
(PIERRE FABRE, Toulouse, France)

12:00 PL22 - Creating, Varying and Selecting : The Driving Forces in Drug Discovery and Chemical Biology Pierre Fabre Award lecture

Benoit DEPREZ
(INSTITUT PASTEUR OF LILLE, Lille, France)

13:00 RICT 2017 Closing remarks & Prizes (Reaxys Award, Poster Prizes)

Sebastien PAPOT
(UNIVERSITY OF POITIERS, Poitiers, France)

13:15 Introduction to RICT 2018

Dominique BONNET
(CNRS-UNIVERSITY OF STRASBOURG, Illkirch, France)

13:30 End of symposium

14:45 Optional visit of the Airbus Facilities